|
1
|
Schreiber AB, Libermann TA, Lax I, Yarden
Y and Schlessinger J: Biological role of epidermal growth
factor-receptor clustering. Investigation with monoclonal
anti-receptor antibodies. J Biol Chem. 258:846–853. 1983.PubMed/NCBI
|
|
2
|
Lemmon MA, Schlessinger J and Ferguson KM:
The EGFR family: Not so prototypical receptor tyrosine kinases.
Cold Spring Harb Perspect Biol. 6:a0207682014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Akiyama T, Sudo C, Ogawara H, Toyoshima K
and Yamamoto T: The product of the human c-erbB-2 gene: A
185-kilodalton glycoprotein with tyrosine kinase activity. Science.
232:1644–1646. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Slamon D, Clark G, Wong S, Levin W,
Ullrich A and McGuire W: Human breast cancer: Correlation of
relapse and survival with amplification of the HER-2/neu oncogene.
Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Toikkanen S, Helin H, Isola J and Joensuu
H: Prognostic significance of HER-2 oncoprotein expression in
breast cancer: A 30-year follow-up. J Clin Oncol. 10:1044–1048.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Seshadri R, Firgaira FA, Horsfall DJ,
McCaul K, Setlur V and Kitchen P: Clinical significance of
HER-2/neu oncogene amplification in primary breast cancer. The
South Australian Breast Cancer Study Group. J Clin Oncol.
11:1936–1942. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sjogren S, Inganäs M, Lindgren A, Holmberg
L and Bergh J: Prognostic and predictive value of c-erbB-2
overexpression in primary breast cancer, alone and in combination
with other prognostic markers. J Clin Oncol. 16:462–469. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Scorilas A, Yotis J, Pateras C, Trangas T
and Talieri M: Predictive value of c-erbB-2 and cathepsin-D for
Greek breast cancer patients using univariate and multivariate
analysis. Clin Cancer Res. 5:815–821. 1999.PubMed/NCBI
|
|
9
|
Ludovini V, Gori S, Colozza M, Pistola L,
Rulli E, Floriani I, Pacifico E, Tofanetti FR, Sidoni A, Basurto C,
et al: Evaluation of serum HER2 extracellular domain in early
breast cancer patients: Correlation with clinicopathological
parameters and survival. Ann Oncol. 19:883–890. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Piccart-Gebhart MJ, Procter M,
Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga
J, Bell R, Jackisch C, et al: Trastuzumab after adjuvant
chemotherapy in HER2-positive breast cancer. N Engl J Med.
353:1659–1672. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gianni L, Dafni U, Gelber RD, Azambuja E,
Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch
C, et al: Treatment with trastuzumab for 1 year after adjuvant
chemotherapy in patients with HER2-positive early breast cancer: A
4-year follow-up of a randomised controlled trial. Lancet Oncol.
12:236–244. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Romond EH, Perez EA, Bryant J, Suman VJ,
Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman
PA, et al: Trastuzumab plus adjuvant chemotherapy for operable
HER2-positive breast cancer. N Engl J Med. 353:1673–1684. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Slamon D, Eiermann W, Robert N, Pienkowski
T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, et
al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J
Med. 365:1273–1283. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Han X, Diao L, Xu Y, Xue W, Ouyang T, Li
J, Wang T, Fan Z, Fan T, Lin B and Xie Y: Association between the
HER2 Ile655Val polymorphism and response to trastuzumab in women
with operable primary breast cancer. Ann Oncol. 25:1158–1164. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tommasi S, Fedele V, Lacalamita R, Bruno
M, Schittulli F, Ginzinger D, Scott G, Eppenberger-Castori S,
Calistri D, Casadei S, et al: 655Val and 1170Pro ERBB2 SNPs in
familial breast cancer risk and BRCA1 alterations. Cell Oncol.
29:241–248. 2007.PubMed/NCBI
|
|
16
|
Fleishman SJ, Schlessinger J and Ben-Tal
N: A putative molecular-activation switch in the transmembrane
domain of erbB2. Proc Natl Acad Sci USA. 99:15937–15940. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jorissen RN, Walker F, Pouliot N, Garrett
TP, Ward CW and Burgess AW: Epidermal growth factor receptor:
Mechanisms of activation and signalling. Exp Cell Res. 284:31–53.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang X, Gureasko J, Shen K, Cole PA and
Kuriyan J: An allosteric mechanism for activation of the kinase
domain of epidermal growth factor receptor. Cell. 125:1137–1149.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jo UH, Han SG, Seo JH, Park KH, Lee JW,
Lee HJ, Ryu JS and Kim YH: The genetic polymorphisms of HER-2 and
the risk of lung cancer in a Korean population. BMC cancer.
8:3592008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Benusiglio PR, Lesueur F, Luccarini C,
Conroy DM, Shah M, Easton DF, Day NE, Dunning AM, Pharoah PD and
Ponder BA: Common ERBB2 polymorphisms and risk of breast cancer in
a white British population: A case-control study. Breast Cancer
Res. 7:R204–R209. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Han W, Kang D, Lee JE, Park IA, Choi JY,
Lee KM, Bae JY, Kim S, Shin ES, Lee JE, et al: A haplotype analysis
of HER-2 gene polymorphisms: Association with breast cancer risk,
HER-2 protein expression in the tumor, and disease recurrence in
Korea. Clin Cancer Res. 11:4775–4782. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Breyer JP, Sanders ME, Airey DC, Cai Q,
Yaspan BL, Schuyler PA, Dai Q, Boulos F, Olivares MG, Bradley KM,
et al: Heritable variation of ERBB2 and breast cancer risk. Cancer
Epidemiol Biomarkers Prev. 18:1252–1258. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tong SY, Ha SY, Ki KD, Lee JM, Lee SK, Lee
KB, Kim MK, Cho CH and Kwon SY: The effects of obesity and HER-2
polymorphisms as risk factors for endometrial cancer in Korean
women. BJOG. 116:1046–1052. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Stanton SE, Ward MM, Christos P, Sanford
R, Lam C, Cobham MV, Donovan D, Scheff RJ, Cigler T, Moore A, et
al: Pro1170 Ala polymorphism in HER2-neu is associated with risk of
trastuzumab cardiotoxicity. BMC cancer. 15:2672015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wittekind C: 2010 TNM system: On the 7th
edition of TNM classification of malignant tumors. Pathologe.
31:331–332. 2010.(In German). View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wittekind C: Lymph nodes, tumour deposits,
and TNM: Are we getting better? 7th edition of UICC 2010 TNM
classification of malignant tumors. Strahlenther Onkol.
188:191–192. 2012.(In German). View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wolff AC, Hammond ME, Hicks DG, Dowsett M,
McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M,
Fitzgibbons P, et al: Recommendations for human epidermal growth
factor receptor 2 testing in breast cancer: American Society of
Clinical Oncology/College of American Pathologists clinical
practice guideline update. J Clin Oncol. 31:3997–4013. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Franklin MC, Carey KD, Vajdos FF, Leahy
DJ, de Vos AM and Sliwkowski MX: Insights into ErbB signaling from
the structure of the ErbB2-pertuzumab complex. Cancer Cell.
5:317–328. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Honegger AM, Kris RM, Ullrich A and
Schlessinger J: Evidence that autophosphorylation of solubilized
receptors for epidermal growth-factor is mediated by intermolecular
cross-phosphorylation. Proc Natl Acad Sci USA. 86:925–929. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Alvarez CV, Shon KJ, Miloso M and Beguinot
L: Structural requirements of the epidermal growth-factor receptor
for tyrosine phosphorylation of Eps8 and Eps15, substrates lacking
Src Sh2 homology domains. J Biol Chem. 270:16271–16276. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wood ER, Truesdale AT, McDonald OB, Yuan
D, Hassell A, Dickerson SH, Ellis B, Pennisi C, Horne E, Lackey K,
et al: A unique structure for epidermal growth factor receptor
bound to GW572016 (Lapatinib): Relationships among protein
conformation, inhibitor off-rate and receptor activity in tumor
cells. Cancer Res. 64:6652–6659. 2004. View Article : Google Scholar : PubMed/NCBI
|
